Mesoblast Limited (ASX:MSB)
1.810
-0.075 (-3.98%)
Nov 17, 2026, 11:22 AM AEDT
Mesoblast Revenue
In the fiscal year ending June 30, 2026, Mesoblast had annual revenue of $120.25M USD with 599.21% growth. Mesoblast had revenue of $68.91M in the half year ending June 30, 2026, with 2,640.97% growth. That makes Mesoblast the 21,485th largest company in the world by revenue and 357th in Australia.
Revenue
$120.25M
Revenue Growth
+599.21%
P/S Ratio
14.08
Revenue / Employee
$1.11M
Employees
108
Market Cap
2.35B AUD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 120.25M | 103.05M | 599.21% |
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 22.79M | 115.31% |
| Jun 30, 2015 | 19.76M | -3.63M | -15.52% |
| Jun 30, 2014 | 23.39M | -8.33M | -26.26% |
| Jun 30, 2013 | 31.72M | -7.41M | -18.93% |
| Jun 30, 2012 | 39.12M | -90.48M | -69.81% |
| Jun 30, 2011 | 129.60M | 128.97M | 20,433.19% |
| Jun 30, 2010 | 631.18K | -89.51K | -12.42% |
| Jun 30, 2009 | 720.69K | -152.06K | -17.42% |
| Jun 30, 2008 | 872.75K | -553.16K | -38.79% |
| Jun 30, 2007 | 1.43M | -669.68K | -31.96% |
| Jun 30, 2006 | 2.10M | 1.71M | 447.74% |
| Jun 30, 2005 | 382.59K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.29B |
| Clinuvel Pharmaceuticals | 94.02M |
| BLS Pharmaceuticals | 73.91M |
| Neuren Pharmaceuticals | 69.53M |
| PYC Therapeutics | 25.99M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
| Clarity Pharmaceuticals | 10.53M |
Mesoblast News
- 8 hours ago - Mesoblast Limited Announces Appointment of Jon Voigtman as Director on 10 November 2026 - Nasdaq
- 1 day ago - Mesoblast Showcased at ASX Premier Investor Day Event - GlobeNewsWire
- 1 day ago - Mesoblast Slides: Investor presentation - Filings
- 4 days ago - Mesoblast Limited Announces Leadership Changes and Reports US$115M in FY2026 Net Revenue - Nasdaq
- 4 days ago - Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout - MarketBeat
- 7 days ago - Mesoblast Transcript: AGM 2026 - Transcripts
- 7 days ago - Mesoblast Slides: FY 2026 - Filings
- 10 days ago - Mesoblast Shares Drop 6% as Stem Cell Developer Slides in Risk-Off Trade Despite 44% Jump in Ryoncil Revenue - International Business Times (Australia)